Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib for autoimmune bullous diseases (IABD)
jRCTs051180069Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of imatinib in Immunobullous disease (IBD), pemphigus and pemphigoid (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: PDAI/BPDAI. Started Apr 2018; status: completed.
02
Drugs
03
Conditions
Immunobullous disease (IBD)pemphiguspemphigoid
Beyond the preview
Go deeper on jRCTs051180069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180069.